Tijani Maha, Munis Altar M, Perry Christopher, Sanber Khaled, Ferraresso Marta, Mukhopadhyay Tarit, Themis Michael, Nisoli Ilaria, Mattiuzzo Giada, Collins Mary K, Takeuchi Yasuhiro
Division of Advanced Therapies, National Institute for Biological Standards and Control, South Mimms EN6 3QG, UK.
Division of Infection and Immunity, University College London, London WC1E 6BT, UK.
Mol Ther Methods Clin Dev. 2018 Aug 7;10:303-312. doi: 10.1016/j.omtm.2018.07.013. eCollection 2018 Sep 21.
Retroviral and lentiviral vectors often use the envelope G protein from the vesicular stomatitis virus Indiana strain (VSVind.G). However, lentivector producer cell lines that stably express VSVind.G have not been reported, presumably because of its cytotoxicity, preventing simple scale-up of vector production. Interestingly, we showed that VSVind.G and other vesiculovirus G from the VSV New Jersey strain (VSVnj), Cocal virus (COCV), and Piry virus (PIRYV) could be constitutively expressed and supported lentivector production for up to 10 weeks. All G-enveloped particles were robust, allowing concentration and freeze-thawing. COCV.G and PIRYV.G were resistant to complement inactivation, and, using chimeras between VSVind.G and COCV.G, the determinant for complement inactivation of VSVind.G was mapped to amino acid residues 136-370. Clonal packaging cell lines using COCV.G could be generated; however, during attempts to establish LV producer cells, vector superinfection was observed following the introduction of a lentivector genome. This could be prevented by culturing the cells with the antiviral drug nevirapine. As an alternative countermeasure, we demonstrated that functional lentivectors could be reconstituted by admixing supernatant from stable cells producing unenveloped virus with supernatant containing envelopes harvested from cells stably expressing VSVind.G, COCV.G, or PIRYV.G.
逆转录病毒和慢病毒载体通常使用来自水疱性口炎病毒印第安纳株(VSVind.G)的包膜糖蛋白G。然而,尚未有稳定表达VSVind.G的慢病毒载体生产细胞系的报道,推测是由于其细胞毒性,阻碍了载体生产的简单放大。有趣的是,我们发现VSVind.G以及来自水疱性口炎病毒新泽西株(VSVnj)、科卡尔病毒(COCV)和皮里病毒(PIRYV)的其他水疱病毒糖蛋白G可以组成型表达,并支持慢病毒载体生产长达10周。所有带G包膜的颗粒都很稳定,可进行浓缩和冻融处理。COCV.G和PIRYV.G对补体失活具有抗性,并且通过构建VSVind.G和COCV.G之间的嵌合体,将VSVind.G补体失活的决定因素定位到氨基酸残基136 - 370。可以生成使用COCV.G的克隆包装细胞系;然而,在尝试建立慢病毒生产细胞时,引入慢病毒载体基因组后观察到载体超感染现象。这可以通过用抗病毒药物奈韦拉平培养细胞来预防。作为一种替代对策,我们证明了通过将产生无包膜病毒的稳定细胞的上清液与含有从稳定表达VSVind.G、COCV.G或PIRYV.G的细胞收获的包膜的上清液混合,可以重构成功能正常的慢病毒载体。